IQVIA Holdings Inc. (IQV)
| Market Cap | 44.61B +28.2% |
| Revenue (ttm) | 16.98B +8.2% |
| Net Income | 1.38B +11.2% |
| EPS | 8.08 +16.7% |
| Shares Out | 164.60M |
| PE Ratio | 33.56 |
| Forward PE | 19.89 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,457,044 |
| Open | 265.10 |
| Previous Close | 262.01 |
| Day's Range | 261.77 - 271.68 |
| 52-Week Range | 154.50 - 277.40 |
| Beta | 1.17 |
| Analysts | Strong Buy |
| Price Target | 299.63 (+10.55%) |
| Earnings Date | Oct 27, 2026 |
About IQV
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers ... [Read more]
Financial Performance
In 2025, IQVIA Holdings's revenue was $16.31 billion, an increase of 5.87% compared to the previous year's $15.41 billion. Earnings were $1.36 billion, a decrease of -0.95%.
Financial StatementsAnalyst Summary
According to 22 analysts, the average rating for IQV stock is "Strong Buy." The 12-month stock price target is $299.63, which is an increase of 10.55% from the latest price.
News
Iqvia price target raised to $303 from $276 at Stifel
Stifel raised the firm’s price target on Iqvia (IQV) to $303 from $276 and keeps a Buy rating on the shares. The firm, which expects Iqvia to outperform consensus expectations…
Iqvia selects Veeva clinical operations applications
IQVIA (IQV) and Veeva Systems (VEEV) announced an expansion of their partnership with the selection of Veeva CTMS, eTMF, Study Startup, and Site Connect as enterprise standard applications that will…
IQVIA Selects Veeva Clinical Operations Applications
RESEARCH TRIANGLE PARK, N.C. & PLEASANTON, Calif.--(BUSINESS WIRE)--IQVIA (NYSE:IQV) and Veeva Systems (NYSE: VEEV) today announced an expansion of their partnership with the selection of Veeva CTMS, ...
Iqvia price target raised to $305 from $280 at BofA
BofA raised the firm’s price target on Iqvia (IQV) to $305 from $280 and keeps a Buy rating on the shares. The life science tools sector has further re-rated since…
Iqvia launches Iqvia Life Science Models
Iqvia (IQV) introduced Iqvia Life Science Models to help predict clinical trial outcomes. Iqvia Life Science Models are a suite of purpose-built models for life sciences, combining Iqvia’s proprietary...
Iqvia launches Iqvia Explorer
Iqvia (IQV) introduced Iqvia Explorer to help customers make better-informed commercial decisions. Iqvia Explorer turns complex, one-time analytics projects into an always-on commercial intelligence c...
IQVIA Launches IQVIA Life Science Models to Help Life Sciences Companies Predict Clinical Trial Outcomes
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healt...
IQVIA Launches IQVIA Explorer to Help Life Sciences Companies Make Better Commercial Decisions
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healt...
Iqvia price target raised to $300 from $275 at Mizuho
Mizuho raised the firm’s price target on Iqvia (IQV) to $300 from $275 and keeps an Outperform rating on the shares. The firm adjusted targets in the healthcare facilities and…
Iqvia price target raised to $300 from $275 at Barclays
Barclays analyst Luke Sergott raised the firm’s price target on Iqvia (IQV) to $300 from $275 and keeps an Overweight rating on the shares. The firm adjusted targets in the…
Iqvia resumed with a Buy at UBS
UBS resumed coverage of Iqvia (IQV) with a Buy rating and $345 price target The firm’s channel checks and survey results suggest Iqvia is gaining market share. The company is…
IQVIA to Announce Third-Quarter 2026 Results on October 27, 2026
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the...
Iqvia price target raised to $319 from $247 at RBC Capital
RBC Capital raised the firm’s price target on Iqvia (IQV) to $319 from $247 and keeps an Outperform rating on the shares. The company’s 20 novel drug approvals in Q3,…
Iqvia price target raised to $329 from $300 at Truist
Truist raised the firm’s price target on Iqvia (IQV) to $329 from $300 and keeps a Buy rating on the shares. The firm has met with the company management to…
Iqvia price target raised to $270 from $240 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Iqvia (IQV) to $270 from $240 and keeps an Equal Weight rating on the shares after having hosted the company’s CFO and…
Trade Desk announces expanded integrations with Veeva Crossix, IQVIA Digital
The Trade Desk (TTD) announced expanded integrations with healthcare analytics and measurement providers Veeva (VEEV) Crossix and IQVIA (IQV) Digital. The enhancements give pharma advertisers more gra...
IQVIA Announces Pricing of Senior Notes
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) today announced that its wholly owned subsidiary, IQVIA Inc. (the “Issuer”), priced an offering of $2,000,000,00...
Iqvia announces offering of senior notes
IQVIA (IQV) Holdings announced that its wholly owned subsidiary, IQVIA, intends to raise $2,000,000,000 through an offering of senior notes due 2034. The proceeds from the Notes offering will be…
IQVIA Announces Offering of Senior Notes
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) today announced that its wholly owned subsidiary, IQVIA Inc. (the “Issuer”), intends to raise $2,000,000,000 thr...
Iqvia announces Predictive Clinical Development
IQVIA (IQV) “announced IQVIA Predictive Clinical Development, an AI-powered approach designed to help life sciences sponsors reduce avoidable delays and bring new therapies to patients up to two years...
IQVIA's Predictive Clinical Development Provides Sponsors With Significant Efficiencies to Get Treatments to Market Faster
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, today announced IQVIA Predict...
IQVIA Wins Multiple Industry Awards for AI and Technology Innovation Across Life Sciences and Healthcare
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healt...
IQVIA's AI-Enabled Clinical Decision Support Tool Wins 2026 AI Breakthrough Award for Predictive Modeling Solution of the Year
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healt...
IQVIA Ranked No. 1 Pharmaceutical Technology Provider by Everest Group
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healt...
Iqvia, Medera partner to advance cardiac gene therapy
Iqvia (IQV) and Medera announced a strategic collaboration to accelerate the development of cardiac gene therapies and human-based drug discovery platforms. The collaboration brings together IQVIA’s g...